National Institute for Health and Clinical Excellence (NICE)
Abstract
Prolonged-release exenatide in triple therapy regimens (that is, in combination
with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is
recommended as a treatment option for people with type 2 diabetes as
described in 'Type 2 diabetes: the management of type 2 diabetes (NICE
clinical guideline 87); that is, when control of blood glucose remains or
becomes inadequate (HbA1c ≥ 7.5% [59 mmol/mol] or other higher level agreed
with the individual), and the person has:
a body mass index (BMI) ≥ 35 kg/m2 in those of European family origin (with
appropriate adjustment for other ethnic groups) and specific psychological or
medical problems associated with high body weight or
a BMI < 35 kg/m2, and therapy with insulin would have significant occupational
implications or weight loss would benefit other significant obesity-related
comorbidities
